Within the diverse molecular landscape of NSCLC, receptor tyrosine kinase (RTK) fusions, such as ROS1 gene rearrangement, have gained significant attention due to their oncogenic role and implications for targeted therapies. Here, ROS1 is linked to non-small cell lung carcinoma.